BMRN
BioMarin Pharmaceutical Inc.
Biotechnology
Market Cap$10.50B
5Y Perf.-48.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BMRN vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1721.78T
5Y Perf.-58.6%
BMRN vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BMRN | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $10.50B | $1721.78T |
| Revenue (TTM) | $3.24B | $0.00 |
| Net Income (TTM) | $269M | $-168M |
| Gross Margin | 75.9% | — |
| Operating Margin | 13.8% | — |
| Forward P/E | 12.7x | — |
| Total Debt | $643M | $22M |
| Cash & Equiv. | $1.31B | $194M |
BMRN vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BMRN
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 100 | 51.2 | -48.8% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BMRN vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BMRN leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BMRN
BioMarin Pharmaceutical Inc.
The Income Pick
BMRN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.65
- Rev growth 12.9%, EPS growth -18.6%, 3Y rev CAGR 15.4%
- -32.4% 10Y total return vs DBVT's -86.8%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT is the clearest fit if your priority is momentum.
- +114.1% vs BMRN's -8.5%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BMRN | 12.9% revenue growth vs DBVT's -100.0% |
| Quality / Margins | BMRN | 8.3% margin vs DBVT's 0.3% |
| Stability / Safety | BMRN | Beta 0.65 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +114.1% vs BMRN's -8.5% |
| Efficiency (ROA) | BMRN | 3.4% ROA vs DBVT's -89.0% |
BMRN vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
BMRN vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGBMRN
BMRNBioMarin Pharmaceutic…
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs BMRNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BMRN7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
BMRN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BMRN and DBVT operate at a comparable scale, with $3.2B and $0 in trailing revenue.
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $3.2B | $0 |
| EBITDAEarnings before interest/tax | $521M | -$112M |
| Net IncomeAfter-tax profit | $269M | -$168M |
| Free Cash FlowCash after capex | $767M | -$151M |
| Gross MarginGross profit ÷ Revenue | +75.9% | — |
| Operating MarginEBIT ÷ Revenue | +13.8% | — |
| Net MarginNet income ÷ Revenue | +8.3% | — |
| FCF MarginFCF ÷ Revenue | +23.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -43.2% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $10.5B | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $9.8B | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | 30.33x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.71x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 16.04x | — |
| Price / SalesMarket cap ÷ Revenue | 3.26x | — |
| Price / BookPrice ÷ Book value/share | 1.77x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 14.48x | — |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
BMRN leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BMRN delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-130 for DBVT. BMRN carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), BMRN scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +4.4% | -130.2% |
| ROA (TTM)Return on assets | +3.4% | -89.0% |
| ROICReturn on invested capital | +7.4% | — |
| ROCEReturn on capital employed | +8.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.11x | 0.13x |
| Net DebtTotal debt minus cash | -$669M | -$172M |
| Cash & Equiv.Liquid assets | $1.3B | $194M |
| Total DebtShort + long-term debt | $643M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 16.96x | -189.82x |
BMRN leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BMRN five years ago would be worth $6,946 today (with dividends reinvested), compared to $3,344 for DBVT. Over the past 12 months, DBVT leads with a +114.1% total return vs BMRN's -8.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs BMRN's -17.1% — a key indicator of consistent wealth creation.
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -8.2% | +5.5% |
| 1-Year ReturnPast 12 months | -8.5% | +114.1% |
| 3-Year ReturnCumulative with dividends | -43.1% | +20.4% |
| 5-Year ReturnCumulative with dividends | -30.5% | -66.6% |
| 10-Year ReturnCumulative with dividends | -32.4% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -17.1% | +6.4% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
BMRN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BMRN is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 82.4% from its 52-week high vs DBVT's 76.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 1.26x |
| 52-Week HighHighest price in past year | $66.28 | $26.18 |
| 52-Week LowLowest price in past year | $50.76 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +82.4% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 253K |
BMRN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BMRN as "Buy" and DBVT as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 64.2% for BMRN (target: $90).
| Metric | BMRNBioMarin Pharmace… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $89.64 | $46.33 |
| # AnalystsCovering analysts | 41 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). BMRN leads in 2 (Profitability & Efficiency, Risk & Volatility).
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
BMRN vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BMRN or DBVT a better buy right now?
BioMarin Pharmaceutical Inc.
(BMRN) offers the better valuation at 30. 3x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate BioMarin Pharmaceutical Inc. (BMRN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BMRN or DBVT?
Over the past 5 years, BioMarin Pharmaceutical Inc.
(BMRN) delivered a total return of -30. 5%, compared to -66. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: BMRN returned -32. 4% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BMRN or DBVT?
By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc.
(BMRN) is the lower-risk stock at 0. 65β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 93% more volatile than BMRN relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — BMRN or DBVT?
On earnings-per-share growth, the picture is similar: BioMarin Pharmaceutical Inc.
grew EPS -18. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BMRN or DBVT?
BioMarin Pharmaceutical Inc.
(BMRN) is the more profitable company, earning 10. 8% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — BMRN leads at 77. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BMRN or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 130.
5% to $46. 33.
07Which pays a better dividend — BMRN or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BMRN or DBVT better for a retirement portfolio?
For long-horizon retirement investors, BioMarin Pharmaceutical Inc.
(BMRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). Both have compounded well over 10 years (BMRN: -32. 4%, DBVT: -86. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BMRN and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.